

MAINE STATE LEGISLATURE

The following document is provided by the
LAW AND LEGISLATIVE DIGITAL LIBRARY
at the Maine State Law and Legislative Reference Library
<http://legislature.maine.gov/lawlib>



Reproduced from scanned originals with text recognition applied
(searchable text may contain some errors and/or omissions)

Date:

6/11/25

(Filing No. H-642)

HEALTH COVERAGE, INSURANCE AND FINANCIAL SERVICES

Reproduced and distributed under the direction of the Clerk of the House.

**STATE OF MAINE
HOUSE OF REPRESENTATIVES
132ND LEGISLATURE
FIRST SPECIAL SESSION**

COMMITTEE AMENDMENT "A" to H.P. 1122, L.D. 1687, "An Act to Clarify and Increase Access to HIV Prevention Medications"

Amend the bill by striking out everything after the enacting clause and inserting the following:

'Sec. 1. 22 MRSA §3197 is enacted to read:

§3197. Prescribing, dispensing and administering HIV prevention drugs

1. Definition. As used in this section, unless the context otherwise indicates, "HIV prevention drug" has the same meaning as in Title 32, section 13786-E, subsection 1, paragraph B.

2. Reimbursement for pharmacists prescribing, dispensing and administering HIV prevention drugs. No later than January 1, 2027, the department shall provide reimbursement under the MaineCare program to a pharmacist for prescribing, dispensing and administering HIV prevention drugs under Title 32, section 13786-E. The department:

A. Shall provide coverage for services provided by the pharmacist under this subsection;

B. Shall authorize a pharmacist to bill the carrier and receive direct payment for a service under this subsection that the pharmacist provides to a MaineCare member and shall identify the pharmacist as the provider in the billing and the claims process for payment of the service; and

C. May not impose on a pharmacist a practice, education or collaboration requirement that is inconsistent with or more restrictive than a requirement of state law or an agency or board rule for the pharmacist to receive payment for a service provided under this subsection.

3. Reimbursement model. No later than January 1, 2027, the department shall create and implement under the MaineCare program a reimbursement model to increase access to HIV prevention drugs administered under Title 32, section 13786-E.

ROS

1 **Sec. 2. 24-A MRSA §4317-D, sub-§2**, as enacted by PL 2021, c. 265, §4, is
2 amended to read:

3 **2. Coverage required.** A carrier offering a health plan in this State shall provide
4 coverage for an HIV prevention drug that has been prescribed by a provider or that has
5 been prescribed, dispensed and administered by a pharmacist under Title 32, section
6 13786-E. Coverage under this section is subject to the following.

7 A. If the federal Food and Drug Administration has approved one or more HIV
8 prevention drugs that use the same method of administration, a carrier is not required
9 to cover all approved drugs as long as the carrier covers at least one approved drug for
10 each method of administration with no out-of-pocket cost. Notwithstanding this
11 paragraph, a carrier shall provide coverage with no out-of-pocket cost for HIV
12 prevention drugs for the prevention of the acquisition of HIV infection in accordance
13 with a rating of A or B in the recommendations of the United States Preventive Services
14 Task Force or equivalent rating from a successor organization and guidelines issued by
15 the United States Department of Health and Human Services, Centers for Medicare and
16 Medicaid Services.

17 B. A carrier is not required to cover any preexposure prophylaxis drug or post-
18 exposure prophylaxis drug dispensed or administered by an out-of-network pharmacy
19 provider unless the enrollee's health plan provides an out-of-network pharmacy benefit.

20 C. A carrier may not prohibit, or permit a pharmacy benefits manager to prohibit, a
21 pharmacy provider from prescribing, dispensing or administering any HIV prevention
22 drugs.

23 D. A carrier shall authorize a pharmacist to bill the carrier and receive direct payment
24 for a service that the pharmacist provides to an enrollee pursuant to this section and
25 shall identify the pharmacist as the provider in the billing and claims process for
26 payment for the service. A carrier may not impose on a pharmacist, in order for the
27 pharmacist to receive payment for a service provided pursuant to this section, a
28 practice, education or collaboration requirement that is inconsistent with or more
29 restrictive than a requirement of state law or agency or board rules.

30 **Sec. 3. 24-A MRSA §4317-D, sub-§3**, as enacted by PL 2021, c. 265, §4, is
31 amended to read:

32 **3. Limits on prior authorization and step therapy requirements.** Notwithstanding
33 any requirements in section 4304 or 4320-N to the contrary, a carrier may not subject any
34 HIV prevention drug to any prior authorization or step therapy requirement except as
35 provided in this subsection. If the federal Food and Drug Administration has approved one
36 or more methods of administering HIV prevention drugs, a carrier is not required to cover
37 all of the approved drugs without prior authorization or step therapy requirements as long
38 as the carrier covers at least one approved drug for each method of administration without
39 prior authorization or step therapy requirements. Notwithstanding this subsection, a carrier
40 shall provide coverage without prior authorization or step therapy requirements for HIV
41 prevention drugs for the prevention of the acquisition of HIV infection in accordance with
42 a rating of A or B in the recommendations of the United States Preventive Services Task
43 Force or equivalent rating from a successor organization and guidelines issued by the
44 United States Department of Health and Human Services, Centers for Medicare and
45 Medicaid Services. If prior authorization or step therapy requirements are met for a

1 particular enrollee with regard to a particular HIV prevention drug, the carrier is required
2 to cover that drug with no out-of-pocket cost to the enrollee.

3 **Sec. 4. 32 MRSA §13786-E, sub-§2, ¶B**, as enacted by PL 2021, c. 265, §6, is
4 amended to read:

5 B. A pharmacist shall dispense or administer a preexposure prophylaxis drug in at least
6 a 30-day supply, and up to a 60-day supply of an oral medication, or in one
7 administration of an injectable medication of any duration, as long as all of the
8 following conditions are met:

9 (1) The patient tests negative for HIV infection, as documented by a negative HIV
10 test result obtained within the previous 7 days. If the patient does not provide
11 evidence of a negative HIV test result in accordance with this subparagraph, the
12 pharmacist shall order an HIV test. If the test results are not transmitted directly
13 to the pharmacist, the pharmacist shall verify the test results to the pharmacist's
14 satisfaction. If the patient tests positive for HIV infection, the pharmacist or person
15 administering the test shall direct the patient to a primary care provider and provide
16 a list of primary care providers and clinics within a reasonable travel distance of
17 the patient's residence;

18 (2) The patient does not report any signs or symptoms of acute HIV infection on
19 a self-reporting checklist of acute HIV infection signs and symptoms;

20 (3) The patient does not report taking any contraindicated medications;

21 (4) The pharmacist provides counseling to the patient, consistent with CDC
22 guidelines, on the ongoing use of a preexposure prophylaxis drug. The pharmacist
23 shall notify the patient that the patient must be seen by a primary care provider to
24 receive subsequent prescriptions for a preexposure prophylaxis drug and that a
25 pharmacist may not dispense or administer more than a 60-day supply of a an oral
26 preexposure prophylaxis drug or one administration of an injectable preexposure
27 prophylaxis drug of any duration to a single patient once every 2 years without a
28 prescription;

29 (5) The pharmacist documents, to the extent possible, the services provided by the
30 pharmacist in the patient's record in the patient profile record system maintained
31 by the pharmacy. The pharmacist shall maintain records of preexposure
32 prophylaxis drugs dispensed or administered to each patient;

33 (6) The pharmacist does not dispense or administer more than a 60-day supply of
34 a an oral preexposure prophylaxis drug or one administration of an injectable
35 preexposure prophylaxis drug of any duration to a single patient once every 2 years,
36 unless otherwise directed by a practitioner; and

37 (7) The pharmacist notifies the patient's primary care provider that the pharmacist
38 completed the requirements specified in this paragraph. If the patient does not have
39 a primary care provider, or refuses consent to notify the patient's primary care
40 provider, the pharmacist shall provide the patient a list of physicians, clinics or
41 other health care providers to contact regarding follow-up care.

Sec. 5. Exemption from review. Notwithstanding the Maine Revised Statutes, Title 24-A, section 2752, this Act is enacted without review and evaluation by the Department of Professional and Financial Regulation, Bureau of Insurance.

Sec. 6. Department of Health and Human Services to apply for waiver under Medicaid program. The Department of Health and Human Services shall apply to the United States Department of Health and Human Services, Centers for Medicare and Medicaid Services for any amendment to the state Medicaid plan or for any waiver under the state Medicaid program necessary to implement this Act by January 1, 2027.

Sec. 7. Appropriations and allocations. The following appropriations and allocations are made.

HEALTH AND HUMAN SERVICES, DEPARTMENT OF

Medical Care - Payments to Providers 0147

Initiative: Provides funding for MaineCare reimbursement to pharmacists for HIV prevention medications.

| GENERAL FUND | 2025-26 | 2026-27 |
|---------------------------|----------------|----------------|
| All Other | \$0 | \$1,470 |
| GENERAL FUND TOTAL | \$0 | \$1,470 |

| FEDERAL EXPENDITURES FUND | 2025-26 | 2026-27 |
|--|----------------|-----------------|
| All Other | \$0 | \$15,591 |
| FEDERAL EXPENDITURES FUND TOTAL | \$0 | \$15,591 |

| OTHER SPECIAL REVENUE FUNDS | 2025-26 | 2026-27 |
|--|----------------|----------------|
| All Other | \$0 | \$1,609 |
| OTHER SPECIAL REVENUE FUNDS TOTAL | \$0 | \$1,609 |

Office of MaineCare Services 0129

Initiative: Provides one-time funding for technology costs to implement MaineCare reimbursement to pharmacists for HIV prevention medications.

| GENERAL FUND | 2025-26 | 2026-27 |
|---------------------------|----------------|-----------------|
| All Other | \$0 | \$42,794 |
| GENERAL FUND TOTAL | \$0 | \$42,794 |

| FEDERAL EXPENDITURES FUND | 2025-26 | 2026-27 |
|--|----------------|------------------|
| All Other | \$0 | \$131,360 |
| FEDERAL EXPENDITURES FUND TOTAL | \$0 | \$131,360 |

RC

| | | | |
|---|------------------------------|---------|-----------|
| 1 | HEALTH AND HUMAN SERVICES, | | |
| 2 | DEPARTMENT OF | | |
| 3 | DEPARTMENT TOTALS | 2025-26 | 2026-27 |
| 4 | | | |
| 5 | GENERAL FUND | \$0 | \$44,264 |
| 6 | FEDERAL EXPENDITURES FUND | \$0 | \$146,951 |
| 7 | OTHER SPECIAL REVENUE FUNDS | \$0 | \$1,609 |
| 8 | | | |
| 9 | DEPARTMENT TOTAL - ALL FUNDS | \$0 | \$192,824 |

10

11 Amend the bill by relettering or renumbering any nonconsecutive Part letter or section

12 number to read consecutively.

13 SUMMARY

14 This amendment removes the language in the bill requiring pharmacists to be

15 reimbursed at the same reimbursement rates as physicians for the dispensing or

16 administering of HIV prevention medications. The amendment retains the clarification in

17 the bill that health insurance carriers are required to provide coverage for HIV prevention

18 medications, including injectable preexposure prophylaxis drugs of any duration. The

19 amendment reallocates the provision requiring health insurance carriers to provide

20 coverage for the services provided by pharmacists to the Maine Insurance Code and makes

21 other clarifying changes to the bill. The amendment also adds an appropriations and

22 allocations section.

23 FISCAL NOTE REQUIRED

24 (See attached)

**132nd MAINE LEGISLATURE****LD 1687****LR 2100(02)****An Act to Clarify and Increase Access to HIV Prevention Medications**

Fiscal Note for Bill as Amended by Committee Amendment "A" (H-642)
Committee: Health Coverage, Insurance and Financial Services
Fiscal Note Required: Yes

Fiscal Note

| | FY 2025-26 | FY 2026-27 | Projections FY 2027-28 | Projections FY 2028-29 |
|-----------------------------------|-------------------|-------------------|-----------------------------------|-----------------------------------|
| Net Cost (Savings) | | | | |
| General Fund | \$0 | \$44,264 | \$2,939 | \$2,939 |
| Appropriations/Allocations | | | | |
| General Fund | \$0 | \$44,264 | \$2,939 | \$2,939 |
| Federal Expenditures Fund | \$0 | \$146,951 | \$31,183 | \$31,183 |
| Other Special Revenue Funds | \$0 | \$1,609 | \$3,218 | \$3,218 |
| Revenue | | | | |
| Federal Expenditures Fund | \$0 | \$146,951 | \$31,183 | \$31,183 |
| Other Special Revenue Funds | \$0 | \$1,609 | \$3,218 | \$3,218 |

Fiscal Detail and Notes

The bill includes ongoing General Fund appropriations to the Department of Health and Human Services of \$1,474 in fiscal year 2026-27 to provide reimbursement to pharmacists under the MaineCare program beginning January 1, 2027 for prescribing, dispensing and administering HIV prevention medications in an amount not to exceed a 60-day supply to an individual once every two years. The bill also includes a one-time General Fund appropriation to the department of \$42,974 in fiscal year 2026-27 for technology costs to implement the MaineCare reimbursement to pharmacists. Federal Expenditure Funds allocations are also included for matching funds and Other Special Revenue Funds allocations are included for drug rebates.

Any additional costs to the Department of Professional and Financial Regulation, Maine Board of Pharmacy to implement the provisions of this bill are expected to be minor and can be absorbed within existing budgeted resources.